Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

New England Journal of Medicine

Volumn 348, Issue 9, 2003, Pages 808-816

  Marcellin, Patrick ^a   Chang, Ting Tsung ^b   Lim, Seng Gee ^c   Tong, Myron J ^d   Sievert, William ^e   Shiffman, Mitchell L ^f   Jeffers, Lennox ^g   Goodman, Zachary ^h   Wulfsohn, Michael S ⁱ   Xiong, Shelly ⁱ   Fry, John ⁱ   Brosgart, Carol L ⁱ  

^a BEAUJON HOSPITAL   (France)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^e MONASH UNIVERSITY   (Australia)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

ⁱ GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN; PLACEBO; VIRUS DNA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBLYOPIA; ANOREXIA; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FANCONI ANEMIA; FEMALE; FLATULENCE; FLU LIKE SYNDROME; GENE MUTATION; HEADACHE; HEART INFARCTION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PATIENT SELECTION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK BENEFIT ANALYSIS; SEROCONVERSION; SIDE EFFECT; TIME SERIES ANALYSIS; VERTIGO; VIRUS LOAD; VIRUS MUTATION; WEIGHT REDUCTION;

ADENINE; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; MALE; MIDDLE AGED; PHOSPHONIC ACIDS;

EID: 0037468421     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa020681     Document Type: Article

References (13)

1. Hepatitis B. Fact sheet WHO/204. Geneva: World Health Organization, October 2000. (Accessed January 7, 2003, at http://www.who.int/inf-fs/en/fact204.htm.)
2. Intron A. Kenilworth, N.J.: Schering, 2001 (package insert).
3. Lai C-L, Chien R-N, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-8.
4. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
5. Leung NW, Lai C-L, Guan R, Liaw Y-F. The effect of longer duration of harbouring lamivudine-resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001;34:348A. abstract
6. Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartare-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clin Infect Dis 2001;33:403-5.
7. Heathcote EJ, Jeffers L, Wright T, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. Hepatology 1998;28:Suppl:317A. abstract.
8. Schiff ER, Neuhaus P, Tillman H, et al. Safety and efficacy of adefovir dipivoxil for the treatment of lamivudine resistant HBV in patients post liver transplantation. Hepatology 2001;34:446A. abstract.
9. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
10. Common toxicity criteria, version 2. Bethesda, Md.: National Cancer Institute, 1999. (Accessed February 4, 2003, at http://ctep.info.nih.gov.)
11. Chien R-N, Liaw Y-F, Atkins M. Pretherapy alanine transaminase level as a determinant of hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999;30:770-4.
12. Yang H, Westland CE, Delaney WE IV, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002;36:464-73.
13. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358:718-23.